https://www.selleckchem.com/pr....oducts/pexidartinib-
The genomic assessment would provide the basis for a genomic-based risk and help in oriented decision-making process.Eribulin inhibits microtubule polymerization and suppresses epithelial-mesenchymal transition. Conventional pathology approaches have not identified a precise predictive biomarker for Eribulin. We performed qmIF on pre-treatment tissue from 11 patients (6 TNBC, 5 HGSOC) treated with Eribulin-LF. T-lymphocytes were the dominant immune-subset in TME, with higher levels detected in stroma vs tumor (9% vs 2%). Gr
Like
Comment
Share
